Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov;19(6):755-60.
doi: 10.1111/j.1365-2354.2009.01135.x.

The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain

R D Pockett  1 , D Castellano, P McEwan, A Oglesby, B L Barber, K Chung
Affiliations
Free PMC article

The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain

R D Pockett et al. Eur J Cancer Care (Engl). 2010 Nov.
Free PMC article

Abstract

Metastatic bone disease (MBD) is the most common cause of cancer pain and of serious skeletal-related events (SREs) reducing quality of life. Management of MBD involves a multimodal approach aimed at delaying the first SRE and reducing subsequent SREs. The objective of the study was to characterise the hospital burden of disease associated with MBD and SREs following breast, lung and prostate cancer in Spain. Patients admitted into a participating hospital, between 1 January 2003 and 31 December 2003, with one of the required cancers were identified and selected for inclusion into the study. The index admission to hospital, incidence of patients admitted and hospital length of stay were analysed. There were 28,162 patients identified with breast, lung and prostate cancer. The 3 year incidence rates of hospital admission due to MBD were 95 per 1000 for breast cancer, 156 per 1000 for lung cancer and 163 per 1000 for prostate cancer. For patients admitted following an SRE, the incidence rates were 211 per 1000 for breast cancer, 260 per 1000 for lung cancer and 150 per 1000 for prostate cancer. This study has shown that cancer patients consume progressively more hospital resources as MBD and subsequent SREs develop.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study schema. MBD, metastatic bone disease; SRE, skeletal-related event.
Figure 2
Figure 2
Mean length of stay by disease type and stage. SRE, skeletal-related event.
Figure 3
Figure 3
Mean length of stay by disease type and admission status. SRE, skeletal-related event. formula image elective, formula image emergency.
Figure 4
Figure 4
Inpatient costs by first (formula image) index cancer admission, first (formula image) MBD admission, and first (formula image) SRE admission. MBD, metastatic bone disease; SRE, skeletal-related event.
See this image and copyright information in PMC

References

    1. Berrino F, the EUROCARE Working Group Survival of cancer patients in Europe: the EUROCARE-3 Study. Annals of Oncology. 2003;14(Suppl. 5):v9–v13. - PubMed
    1. Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY, Verma S, Pritchard KI, Trudeau M, Cole DE. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. Journal of Clinical Oncology. 2006;24:4895–4900. - PubMed
    1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treatment Reviews. 2001;27:165–176. - PubMed
    1. Coleman RE. The role of bisphosphonates in breast cancer. Breast. 2004;13(Suppl. 1):S19–28. - PubMed
    1. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. British Journal of Cancer. 1987;55:61–66. - PMC - PubMed

Publication types

MeSH terms